{"nctId":"NCT00389168","briefTitle":"Irbesartan and Atenolol in Hypertensive Heart Disease","startDateStruct":{"date":"1995-04"},"conditions":["Hypertension"],"count":115,"armGroups":[{"label":"Irbesartan","type":"EXPERIMENTAL","interventionNames":["Drug: Irbesartan"]},{"label":"Atenolol","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Atenolol"]}],"interventions":[{"name":"Irbesartan","otherNames":["Aprovel"]},{"name":"Atenolol","otherNames":["Tenormin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 18 ys old\n* Male or female with no child bearing potential\n* Seated blood pressure diastolic 90-115 mm Hg\n* Left ventricular mass above 131 g/m2 for men, above 100 g/m2 for women\n* Informed consent\n\nExclusion Criteria:\n\n* Coronary artery disease, heart failure or other significant cardiac disorder\n* Cerebrovascular accident within the past 6 months\n* A seated systolic blood pressure above 200 mm Hg\n* Significant renal disease, collagen or vascular disease, or gastrointestinal condition\n* Significant allergy or intolerance to study drug\n* Alcohol or drug abuse\n* Uncontrolled diabetes mellitus","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Number of Participants With Serious Adverse Events","description":"Safety was assessed by non-directed questions, and all observed and volunteered adverse events were recorded at each study visit. Serious adverse events were defined by, and reported according to the regulations of good clinical practice (GCP). none were considered related to the study medication.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"PRIMARY","title":"Changes in Left Ventricular Mass Index","description":"Repeated measures multivariate analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks. Data are presented as left ventricular mass in gram (g) indexed for body mass index (in m\\^2).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1","spread":null},{"groupId":"OG001","value":"-9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6","spread":null},{"groupId":"OG001","value":"-14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14","spread":null},{"groupId":"OG001","value":"-26","spread":null}]}]}]},{"type":"SECONDARY","title":"Left Ventricular Diastolic Function Assessed by the E/A Ratio","description":"Changes in left ventricular diastolic function from baseline to week 48 will be evaluated as the difference in E/A ratio. Conventional pulsed wave Doppler echocardiography was used for recordings of mitral inflow in. The peak of early (E) and late (A) mitral flow velocities were measured, and the E/A-ratio was calculated. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Some echocardiographic recordings at some time point may be of insufficient quality or missing, and the number of observations may not always correspond to the total number of participants at all time points.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"0.23"},{"groupId":"OG001","value":"0.10","spread":"0.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"0.28"},{"groupId":"OG001","value":"0.04","spread":"0.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.24"},{"groupId":"OG001","value":"0.10","spread":"0.21"}]}]}]},{"type":"SECONDARY","title":"Blood Pressure","description":"Difference in Diastolic Blood Pressure. Repeated measures multivariable analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.3","spread":null},{"groupId":"OG001","value":"-18.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes of Venous Plasma Angiotensin II as a Marker of the Renin-Angiotensin-Aldosterone System","description":"Venous plasma concentrations of angiotensin II were measured in order to study the possible associations between the activity of the renin-angiotensin-aldosteone system and changes in left ventricular mass. Further analyses of other components of the renin-angiotensin-aldosterone system and of other hormonal system (e.g. the sympathetic nervous system) have also been performed and published. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Data were log-transformed to avoid skewness before statistical evaluation. However, tabular data are given as mean values with 95% confidence to improve readability.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":null},{"groupId":"OG001","value":"3.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":null},{"groupId":"OG001","value":"3.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Effects on Carotid Artery Wall Thickness","description":"Changes in common carotid artery intima-media thickness, assessed by ultrasonography.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.12"},{"groupId":"OG001","value":"-0.01","spread":"0.10"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":56},"commonTop":[]}}}